- Conditions
- Malignant Peripheral Nerve Sheath Tumors, MPNST
- Interventions
- BMS-986504
- Drug
- Lead sponsor
- Ankit Mangla, MD
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 243
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neurofibromatosis Type 2
- Interventions
- REC-2282, Placebo
- Drug
- Lead sponsor
- Recursion Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 8 more
- Conditions
- Neurofibroma, Plexiform, Neurofibromatosis Type I
- Interventions
- tipifarnib, placebo
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
- Conditions
- Neurofibromatosis 1
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 1,046 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Baltimore, California • Redwood City, California
- Conditions
- Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
- Interventions
- Selinexor, Ixazomib
- Drug
- Lead sponsor
- Matthew Ingham
- Other
- Eligibility
- 14 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor, Plexiform Neurofibroma, Optic Glioma, Neurofibroma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Weeks and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neurofibromatosis Type 1, Neurofibromatosis 1, Plexiform Neurofibroma, Plexiform Neurofibromas, Malignant Peripheral Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumors, Atypical Neurofibroma
- Interventions
- Liquid biopsy for MPNST development
- Diagnostic Test
- Lead sponsor
- David Miller
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neurofibromatosis
- Interventions
- ACT Workshop
- Behavioral
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
- Interventions
- Lenalidomide, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
- Conditions
- Vestibular Schwannoma, Meningioma, Acoustic Neuroma, Neurofibromatosis Type 2
- Interventions
- AR-42
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Neurofibromatosis 1
- Interventions
- Peg-Interferon alpha-2b, Celecoxib (Celebrex), Temozolomide (temodar), Vincristine Sulfate (Oncovin)
- Drug
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1), Atypical Neurofibroma
- Interventions
- APG-115, Selumetinib
- Drug
- Lead sponsor
- AeRang Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Sarcoma
- Interventions
- temsirolimus plus liposomal doxorubicin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Endometrial Cancer, Ovarian Cancer, Sarcoma
- Interventions
- temozolomide
- Drug
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neurofibromatosis
- Interventions
- Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma, Glioma
- Interventions
- Selumetinib
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 45 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Neurofibromatosis 1, Scoliosis
- Interventions
- Cheek swab
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Neurofibromatosis Type 1, Plexiform Neurofibroma, Spinal Cord Neurofibroma
- Interventions
- Cediranib Maleate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
- Conditions
- Cutaneous Neurofibroma, Neurofibromatosis 1
- Interventions
- NFX-179 gel, Vehicle gel
- Drug
- Lead sponsor
- NFlection Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Fremont, California + 20 more
- Conditions
- Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Soft Tissue Fibrosarcoma, Spindle Cell Sarcoma, Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Retroperitoneal Sarcoma AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Retroperitoneal Sarcoma AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Retroperitoneal Sarcoma AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Retroperitoneal Sarcoma AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Storiform-Pleomorphic Malignant Fibrous Histiocytoma, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells, Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant, Undifferentiated Spindle Cell Sarcoma
- Interventions
- Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab, Radiation Therapy
- Procedure · Biological · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma (PN)
- Interventions
- Selumetinib, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more
- Conditions
- Neurofibromatosis, MPNST
- Interventions
- MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 10 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sarcoma
- Interventions
- gene expression analysis, polymerase chain reaction, western blotting, neoadjuvant therapy, therapeutic conventional surgery, intensity-modulated radiation therapy
- Genetic · Procedure · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Neurofibromatosis Type 1, Plexiform Neurofibroma
- Interventions
- Binimetinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more